Abstract 238P
Background
Surgery remains the cornerstone of treatment in ovarian cancers with the aim to achieve a complete cytoreduction with no macroscopic residual disease. The present study tries to assess the feasibility of laparoscopic optimal cytoreduction surgery (LOCS) in patients with advanced ovarian cancer (AOC) with low burden disease.
Methods
A retrospective study of advanced ovarian cancer that underwent LOCS between 2010 and 2014 was done. Histologically confirmed epithelial or germ cell ovarian cancer who underwent either interval or primary cytoreduction surgery were included.
Results
In all 40 patients with stage 3 ovarian cancers were included in the analysis. The median age was 50 years and the median BMI was 23 kg/m2. 39 patients had epithelial ovarian cancer (38 – serous, 1- endometrioid) and 1 patient had germ cell tumor. 23 were grade 3 and 17 were grade 2, with no patient in grade 1. Stage wise majority were stage IIIC (26 patients) followed by 3 in stage IIIA and 1 patient was stage IIIB .3 patients underwent primary cytoreduction (1- IIIA, 2- IIIB) and 37 patients received neoadjuvant chemotherapy (NACT) before surgery. 3 to 8 cycles of chemotherapy was given. On the final histopathological examination, complete response was seen in 7 patients. There was no intraoperative complication and one postoperative complication (2.5%). The median time to discharge was 5 days and the median time to start chemotherapy was 23 days. After a median follow up of 70 months 7 patients (17.5%) were lost to follow up. The overall survival was 48.3% and the recurrence-free survival was 27.2 %.19 patients recurred in the peritoneum and 5 patients had a nodal recurrence.
Conclusions
Laparoscopic cytoreduction is feasible in patients with advanced-stage ovarian cancers, provided the disease burden permits optimal debulking, especially so if done in centers with experience in complex laparoscopic procedures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract